From clinical trials to the bedside: How can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials?

Clinical and Experimental Rheumatology

Volumn 23, Issue 6, 2005, Pages 893-904

  Baldini, Chiara ^a   Deel Sedie, Andrea ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anakinra; Anti TNFa; CHV infection; DMARDs; Osteoporosis; Pregnancy; Rheumatoid arthritis; TBC

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BETAMETHASONE; CALCIUM; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VITAMIN D;

ACUTE KIDNEY TUBULE NECROSIS; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ATHEROGENESIS; AZOOSPERMIA; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY THROMBOSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; EMBRYOTOXICITY; ENTERITIS; FETUS MALFORMATION; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOCOMPETENCE; IMMUNOGLOBULIN A NEPHROPATHY; INFERTILITY; KIDNEY AMYLOIDOSIS; KIDNEY DISEASE; LEUKEMIA; LIVER CIRRHOSIS; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; MORTALITY; MULTIPLE MYELOMA; MYCOSIS; OLIGOSPERMIA; OSTEOPOROSIS; POSTOPERATIVE INFECTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TUBERCULOSIS; VIRUS INFECTION;

ARTHRITIS, RHEUMATOID; COMORBIDITY; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 29944432961     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. MAINI RN, ZVAIFLER NJ: Rheumatoid arthritis and other synovial disorders. In KLIPPEL JH and DIEPPE PA: Rheumatology, 2nd ed., 1998 Mosby International, 1998; 5.1.1-5.30.2.
2. EMERY P, SETO Y: Role of biologics in early arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S191-4.
3. QUINN MA, EMERY P: Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S154-7.
4. ALETAHA D, SMOLEN JS: DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S169-73.
5. GOSSEC L, DOUGADOS M: Combination therapy in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S174-8.
6. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S179-85.
7. MULLAN RH, BRESNIHAN B: Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S158-64.
8. KAVANAUGH A, KEYSTONE EC: The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S203-8.
9. O'DELL JR, HAIRE C, ERIKSON N et al.: Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 1996; 44 (Suppl.): 72-4.
10. O'DELL JR, LEFF R, PAULSEN G et al.: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-70.
11. LANDEWE RB, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-56.
12. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
13. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-41.
14. SMOLEN JS: Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol 1999; 112 (Suppl.): 15-21
15. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
16. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
17. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
18. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50.
19. St CLAIR EW, van der HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
20. COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a 24-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-2.
21. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
22. SMOLEN JS, SOKKA T, PINCUS T, BREEDVELD FC: A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S209-10.
23. O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350: 2591-602.
24. MIKULS TR, SAAG KG: Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 283-302.
25. CSEPREGI A, NEMESANSZKY E, ROJKOVICH B, POOR G: Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link. J Rheumatol 2001; 28: 474-7.
26. MAILLEFERT JF, MULLER G, FALGARONE G et al.: Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 635-7.
27. RIVERA J, GARCIA-MONFORTE A, PINEDA A, MILLAN NUNÉZ-CORTES J: Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999; 26: 420-4.
28. ALLALI F, RKAIN H, FAIK A, EL HASSANI S, HAJJAJ-HASSOUNI N: Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients. Clin Rheumatol 2005; 24: 656-7.
29. JURIK AG, DAVIDSEN D, GRAUDAL H: Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol 1982; 11: 217-24.
30. KROOT EJJA, van GESTEL AM, SWINKELS HL, ALBERS MMC, van de PUTTE LBA, van RIEL PLCM: Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 2001; 28: 1511-7.
31. BERKANOVIC E, HURWICZ M: Rheumatoid arthritis and comorbidity. J Rheumatol 1990; 17: 888-92.
32. PARODI M, BENSI L, MAIO T, MELA GS, CIMMINO MA: Comorbidities in rheumatoid arthritis: analysis of hospital discharge records. Reumatismo 2005; 57: 154-60.
33. WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305-11.
34. EKSTROM K, HJALGRIM H, BRANDT L et al.: Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48: 963-70.
35. CIBERE J, SIBLEY J, HAGA M: Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40: 1580-6.
36. PETERSON JR, HSU FC, SIMKIN PA, WENER MH: Effect of tumour necrosis factor antagonist on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-82.
37. LOK AS, LIANG RH, CHIU EK, WONG KL, CHAN TK, TODD D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
38. ZUCKERMAN E, ZUCKERMAN T, DOUER D, QIAN D, LEVINE AM: Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematological malignancies. Cancer 1998; 83: 1224-30.
39. KUJAWSKA A, CLEMENTS M, WISE CM, ROBERTS WN: Hepatitis C and methotrexate. Arthritis Rheum 2003; 49: 843-5.
40. ZUCKERMAN E, YESHURUN D, ROSNER I: Management of hepatitis C virus-related arthritis. BioDrugs 2001; 15: 573-84.
41. MOK MY, NG WL, YUEN MF, WONG RW, LAU CS: Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363-8.
42. WHITING-O'KEEFE QE, FYE KH, SACK KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-6.
43. HAGIYAMA H, KUBOTA T, KOMANO Y, KUROSAKI M, WATANABE M, MIYASAKA N: Fulminat hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: 375-6.
44. GONZÁLEZ JA, CALVO J, HERRERA A, HORTELANO E, FOLGADO J, LÓPEZ MD: Hepatopatia mixta por sales de oro via parenteral. Ann Med Interne 1990; 7: 477-9.
45. SEVILLA-MANTILLA C, ORTEGA L, AGÚNDEZ JAG, FERNÁNDEZ-GUTIÉRREZ B, LADERO JM, DÍAZ-RUBIO M: Leflunomide-induced acute hepatitis. Dig Liver Dis 2004; 36: 82-4.
46. LEGRAS A, BERGEMER-FOUQUET AM, JOINVILLE-BERA AP: Fatal hepatitis with leflunomide and itraconazole. Am J Med 2002; 113: 352-3
47. WEINBLATT ME, DIXON JA, FALCHUK KR: Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000;43:2609-11
48. van RIEL PLCM, SMOLEN JS, EMERY P, et al.: Leflunomide: a manageable safety profile. J Rheumatol 2004; 31 (Suppl. 71): 21-4
49. CANNON G, SCHIFF M, STRAND V, HOLDEN W: Hepatic adverse events and other toxicity during treatment with leflunomide, methotrexate, other disease modifying antirheumatic drugs (DMARDs), and combination DMARD therapy: comparison to NSAID alone and adjustment for comorbidities category. Arthritis Rheum 2002; 46 (Suppl.): S357.
50. SUISSA S, ERNST P, HUDSON M, BITTON A, KEZOUH A: Newer disease-modifying antirheumatic drugs and the risk of serious adverse events in patients with theumatoid arthritis. Am J Med 2004; 117: 87-92.
51. NAKAGAWA M, SAKAMOTO N, ENOMOTO N et al.: Specific inibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 42-7.
52. INOUE K, SEKIYAMA K, YAMADA M, WATANABE T, YASUDA H, YOSHIBA M: Combined interferon 2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-72.
53. WATASHI K, HIJIKATA M, HOSAKA M, YAMAJI M, SHIMOTOHNO K: Cyclosporin A suppress replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
54. HERBEIN G, O'BRIEN WA: Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000; 223: 241-57.
55. BIANCONE L, Del VECCHIO BLANCO G, PALLONE F et al.: Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002; 122: 593-4.
56. CAMPBELL S, GHOSH S: Infliximab treatment for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13: 191-2.
57. PETERSON JR, HSU FC, SIMKIN PA, WENER MH: Effect of tumour necrosis factor antagonist on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-82.
58. PARKE FA, REVEILLE JD: Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 800-4.
59. ONIANKITAN O, DUVOUX C, CHALLINE D et al.: Infliximab therapy for rheumatic diseases in patients with chronic hepatitits B or C. J Rheumatol 2004; 31: 107-9.
60. BAHRA M, NEUMANN UP, HARREN M et al.: Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. Transplantation Proceedings 2002; 34: 2934-5.
61. ICARDI A, ARAGHI P, CIABATTONI M, ROMANO U, LAZZARINI P, BIANCHI G: Kidney involvement in rheumatoid arthritis. Reumatismo 2003; 55: 76-85.
62. COHEN DJ, APPEL GB: Cyclosporine: nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis. Semin Arthritis Rheum 1992; 21 (Suppl. 3): 43-8.
63. WILLIAMS HJ, WILLKENS RF, SAMUELSON CO Jr et al.: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1985; 28: 751-30.
64. SEIDEMAN P, MULLER-SUUR R, EKMAN E: Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126-58.
65. REILLY P, COSH J, MADDISON P, RASKER JJ, SILMAN AJ: Mortality and survival in rheumatoid arthritis: a 25 prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-9.
66. ICARDI A, ARAGHI P, CIABATTONI M, ROMANO U, LAZZARINI P, BIANCHI G: Coinvolgimento renale in corso di artrite reumatoide. Kidney involvement in rheumatoid arthritis. Reumatismo 2003; 55: 76-85.
67. WILAND P, WIELA-HOJENSKA A, GLOWSKA A et al.: Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab. Clin Exp Rheumatol 2004; 22: 469-72.
68. WILAND P, WIELA-HOJENSKA A, SWIERKOT J et al.: Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose methotrexate. Pol Arch Med Wewn 2003; 110: 855-62.
69. MIKULS TR: Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17: 729-52.
70. WADA Y, KURODA T, MURASAWA A, TANABE N, NAKANO M, GEJYO F: Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 482-6.
71. TORZEWSKI J, BOWYER D, WALTENBERG J, FITZSIMMONS C: Process in atherogenesis: complement activation. Atherosclerosis 1997; 132: 131-8.
72. KREMER JM, CANNON GW: Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S95-100.
73. GREMESE E, FERRACCIOLI GF: Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S101-7.
74. NASHEL D: Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 1986; 80: 925-9.
75. PARK YB, LEE SK, LEE WK et al.: Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-4.
76. MORGAN SL, BAGGOTT JE, LEE JY, ALARCON GS: Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25: 441-6.
77. RAU R, HERBORN G: Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S83-94.
78. IMPERATO AK, BINGHAM CO 3rd, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S108-14.
79. CUSH JJ: Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S141-7.
80. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46(9):2294-300.
81. DOBLOUG JH, FORRE O, KVIEN TK, EGELAND T, DEGRE M: Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis 1982; 41: 490-4.
82. BOTSIOS C: Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005; 4: 162-70.
83. BIEBER J, KAVANAUGH A: Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S126-33.
84. BINYMIN K, COOPER RG: Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 341-2.
85. HERNANDEZ-CRUZ B, PONCE-DE-LEON-ROSALES S, SIFUENTES-OSORNIO J, PONCE-DE-LEON-GARDUNO A, DIAZ-JOUANEN E: Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol 1999; 17: 81-7.
86. WINTHROP KL: Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor. Ann Rheum Dis 2005; 64: iv29-30.
87. SINGH N, PATERSON DL: Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27: 1266-77.
88. MUFTI AH, TOYE BW, McKENDRY RR, ANGEL JB: Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 2005 Oct 21; (epub ahead of print).
89. MELLEMKJAKER L, LINET MS, GRIDLEY G, FRISCH M, MOLLER H, OLSEN JH: Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A (10): 1753-7.
90. van VOLLENHOVEN RE: Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S122-5.
91. GABRIEL SE, CROWSON CS, O'FALLON WM: Comorbidity in arthritis. J Rheumatol 1999; 26: 2475-9.
92. GABRIEL SE, JAAKKIMAINEN L, BOMBARDIER C: Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991: 115: 787-96.
93. OSTENSEN M: New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 2004; 18: 219-32.
94. PRIDDY AR, KILLICK SR, ELSTEIN M et al.: The effect of prostaglandin synthetase inhibitors on human preovulatoryfollicular fluid prostaglandin, thromboxane, and leukotriene concentrations. J Clin Endocrinol Metab 1990; 71: 235-42.
95. TEMPRANO KK, BANDLAMUDI R, MOORE TL: Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35: 112-21.
96. SOOKVANICHSILP N, PULBUTR P: Anti-implantation effects of indomethacin and celecoxib in rats. Contraception 2002; 65: 373-8.
97. PALL M, FRIDEN BE, BRANNSTROM M: Induction of delayed follicular rupture in the human by the selective COX-2inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16: 1323-8.
98. O'MORAIN C, SMETHURST P, DORE CJ, LEVI AJ: Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25: 1078-84.
99. JANSSEN NM, GENTA MS: The effects of immunosuppressive and anti-inflammatory medications onfertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610-9.
100. CHAKRAVARTY EF, SANCHEZ-YAMAMOTO D, BUSH TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30: 241-6.
101. OSTENSEN M: Drugs in pregnancy. Rheumatological disorders. Best Pract Res Clin Obstet Gynaecol 2001; 15: 953-69.
102. MILUNSKY A, GRAFF JW, GAYNOR MF Jr: Methotrexate-induced congenital malformations. J Pediatr 1968; 72: 790-5.
103. POWELL HR, EKERT H: Methotrexate-induced congenital malformations. Med J Aust 1971; 2: 1076-7.
104. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-31.
105. ANTONI CE, FURTS D, MANGER B et al.: Outcome of pregnancy in women receiving Remicade (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis. Arthritis Rheum 2001; 44: S152.
106. KEYSTONE E, HARAOUI B: Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30: 349-64.
107. KAVANAUGH AF: Rheumatoid arthritis in the elderly: is it a different disease? Am J Med 1997; 103 (6A): S40-8.
108. MAVRAGANI CP, MOUTSOPOULOS HM: Rheumatoid arthritis in the elderly. Exp Gerontol 1999; 34: 463-71.
109. BAJOCCHI G, La CORTE R, LOCAPUTO A, GOVONI M, TROTTA F: Elderly onset rheumatoid arthritis: clinical aspects. Clin Exp Rheumatol 2000; 18 (Suppl. 20):S49-50.
110. van der HEIJDE DM, van RIEL PL, van LEEUWEN MA, van 't HOF MA, van RIJSWIJK MH, van de PUTTE LB: Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol 1991; 18: 1285-9.
111. van SCHAARDENBURG D, BREEDVELD FC: Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 1994; 23: 367-78.
112. PAPADOPOULOS IA, KATSIMBRI P, ALAMANOS Y, VOULGARI PV, DROSOS AA: Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003; 23: 70-4.
113. SÄLLFORS C, HALLBERG LR-M, FASTH A: Well-being in children with juvenile chronic arthritis. Clin Exp Rheumatol 2004; 22: 125-30.
114. DROSOS A: Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging 2003; 20: 723-36.
115. FLEISCHMANN R, BAUMGARTNER SW, WEISMAN M, LIU T, WHITE B, PELOSO PM: Long-term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2005; 2005 Sep 21 (Epub ahead of print).
116. Di MUNNO O, DELLE SEDIE A, ROSSINI M, ADAMI S: Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 137-44.
117. ORSTAVIK RE, HAUGEBERG G, MOWINCKEL P et al.: Vertebral deformities in rheumatoid arthritis. Arch Intern Med 2004; 164: 420-5.
118. ORSTAVIK RE, HAUGEBERG G, UHLIG T et al.: Self reported nonvertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 2004; 63: 177-82.
119. KROOT EJ, LAAN RF: Bone mass in rheumatoid arthritis. Clin Exp Rheumatol 2000; 18 (Suppl. 21): S12-5.
120. LODDER MC, de JONG Z, KOSTENSE PJ et al.: Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004; 63: 1576-80.
121. SCHAPIRA D, SCHARF Y: Insufficiency fracture of the distal tibia mimicking arthritis in a rheumatoid arthritis patient. The possible role of methotrexate treatment. Clin Exp Rheumatol 1995; 13: 130-1.
122. MAENAUT K, WESTHOVENS R, DEQUEKER J: Methotrexate osteopathy, does it exist? J Rheumatol 1996; 23: 2156-9.
123. ALONSO-BARTOLOMÈ P, MARTINEZ-TABOADA VM, BLANCO R, RODRIGUEZ-VALVERDE V: Insufficiency fractures of the tibia and fibula. Semin Arthritis Rheum 1999; 28: 413-20.
124. SUZUKI Y, NAKAGAWA M, MASUDA C et al.: Short-term low-dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvan-induced arthritis. J Rheumatol 1997; 24: 1890-5.
125. El MEDIANY YM, ABUBAKR IH, El BADDINI M: Effect of low dose methorexate on markers of bone metabolism in patients with rheumatoid arthritis. J Rheumatol 1998; 25: 2083-7.
126. MINAUR NJ, KOUNALI D, VEDI S, COMPSTON JE, BERESFORD JN, BHALLA AK: Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 2002; 41: 741-9.
127. MOVSOWITZ C, EPSTEIN S, FALLON M, ISMAIL F, THOMAS S: Cyclosporin A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571-7.
128. JULIAN BA, LASKOW DA, DUBOVSKY J, DUBOVSKY EV, CURTIS JJ, QUARLES LD: Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-50.
129. AROLDI A, TARANTINO A, MONTAGNINO G, CESANA B, COCUCCI C, PONTICELLI C: Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997; 63: 380-6.
130. FERRACCIOLI G, CASATTA L, BARTOLI E: Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. J Rheumatol 1996; 23: 1539-42.
131. FISCHER VW, FITCH CD: Affinity of chloroquine for bone. J Pharm Pharmacol 1975; 27: 527-9.
132. JULKUNEN H, ROKKANEN P, LAINE H: Chloroquine treatment and bone changes in rheumatoid arthritis. Scand J Rheumatol 1976; 5: 36-8.
133. URUSHIBARA M, TAKAYANAGI H, KOGA T et al.: The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004; 50: 794-804.
134. OSTANEK L, PAWLIK A, BRZOSKO I et al.: The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab. Clin Rheumatol 2004; 23: 214-7.
135. KORCZOWSKA I, HRYCAJ P, LACKI JK: Change in biomarkers of osteoporosis in rheumatoid arthritis patients treated with infliximab. Pol Arch Med Wewn 2004; 111: 673-8.
136. VIS M, VOSKUYL AE, WOLBINK GJ et al.: Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis 2005; 64: 336-7.
137. LANGE U, TEICHMANN J, MULLER-LADNER U, STRUNK J: Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-{alpha} antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005 Nov 1 (Epub ahead of print).
138. ALLALI F, BREBAN M, PORCHER R, MAILLEFERT JF, DOUGADOS M, ROUX C: Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003; 62: 347-9.
139. MARZO-ORTEGA H, McGONAGLE D, HAUGEBERG G, GREEN MJ, STEWART SP, EMERY P: Bone mineral density improvement in spondyloarthropathy after treatment with etanercept. Ann Rheum Dis 2003; 62: 1020-1.
140. BRIOT K, GARNERO P, LE HENANFF A, DOUGADOS M, ROUX C: Body weight, body composition and bone turnover changes in patients with spondyloarthropathy receiving anti-TNFalpha treatment. Ann Rheum Dis 2005 Jan 7 (Epub ahead of print).
141. INOUE T, KAWAMURA I, MATSUO M et al.: Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. Transplantation 2000; 70: 774-9.
142. DISSANAYAKE I, GOODMAN G, BOWMAN A et al.: Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275.
143. MONEGAL A, NAVASA M, GUANABENS N, PERIS P, PONS F: Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68: 83-6.
144. BRYER HP, ISSEROW JA, ARMSTRONG EC et al.: Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10: 132-8.